Support The Moscow Times!

Russia’s Ebola Vaccine Ready For ‘Human Use’

Abbas Dulleh / AP

A Russian vaccine against Ebola is ready to be licensed for use in humans, the head of Russia's state health watchdog has announced.

Russia's Vaktora vaccine tested well in clinical trials, Rospotrebnadzor chief Anna Popova said Thursday.

The vaccine has shown to be up to 100 percent effective after two doses, the Interfax news agency reported.

More than 11,300 people died during an Ebola outbreak in Western Africa in 2013.

A vaccine developed by GlaxoSmithKline and the U.S. government has been used in human trials in the region alongside another vaccine developed by Newlink Genetics and Merck.

West Africa was declared Ebola free in June 2016, but the World Health Organization has warned that new flare-ups are still likely.

Russia dedicated $19 million to fighting the outbreak in October 2014 primarily by providing humanitarian aid.

The virus, which causes vomiting, diarrhea, liver failure and internal and external bleeding, kills approximately 50 percent of those who contract the illness.

Read more

Independent journalism isn’t dead. You can help keep it alive.

As the only remaining independent, English-language news source reporting from Russia, The Moscow Times plays a critical role in connecting Russia to the world.

Editorial decisions are made entirely by journalists in our newsroom, who adhere to the highest ethical standards. We fearlessly cover issues that are often considered off-limits or taboo in Russia, from domestic violence and LGBT issues to the climate crisis and a secretive nuclear blast that exposed unknowing doctors to radiation.

As we approach the holiday season, please consider making a one-time donation — or better still a recurring donation — to The Moscow Times to help us continue producing vital, high-quality journalism about the world’s largest country.